SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-039221
Filing Date
2024-09-04
Accepted
2024-09-04 07:01:31
Documents
13
Period of Report
2024-09-03
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K avtx-20240903.htm   iXBRL 8-K 23739
  Complete submission text file 0001628280-24-039221.txt   143039

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20240903.xsd EX-101.SCH 1969
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20240903_lab.xml EX-101.LAB 21026
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20240903_pre.xml EX-101.PRE 12041
15 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20240903_htm.xml XML 2625
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

IRS No.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37590 | Film No.: 241275839
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)